If Only Steve Jobs Had Known PharmaCyte and Biotech Cell-in-a-Box Print E-mail
By OTC Journal.com   
Thursday, 17 September 2015 10:54

If only Steve Jobs had access to this therapy before Pancreatic Cancer took his life. Had he known of PharmaCyte Biotech's (PMCB) live-cell encapsulation technology then, he may still be with us.

A diagnosis of Pancreatic Cancer is considered tantamount to a death sentence. Pancreatic Cancer has no warning signs, and is therefore rarely detected until the very late stages. Hence, it's one of the most difficult cancers to treat.

Something amazing happened in the late 1990's and the early part of the 21st Century. There were two studies done using a new technology for treating Pancreatic Cancer. At a clinic in Germany14 patients with Stage III and Stage IV Pancreatic Cancer were treated. The standard chemotherapy was used - but it was delivered in a new and revolutionary manner. Instead of the usual shot gun effect from Chemotherapy in the blood stream, a technology that targeted the toxic medicine with laser like accuracy directly at the tumors dramatically improved outcome and lowered toxicity.

Capsules the size of the head of a pin were placed near the tumors through a catheter. These unique capsules contained genetically modified cells that are capable of activitating the anticancer drug infosfamide at the site of the tumor instead of the liver, which allows the chemotherapy drug to be activated right at the site of the tumor. Much like a laser guided missle, the capsule paints the target for the chemotherapy drug.

 

 

 

READ THE REST OF THE ARTICLE HERE AT OTCJOURNAL.COM




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter